INTRODUCTION
============

Colonoscopy with polypectomy is the gold standard for removing precancerous polyps of the colon. The process of identification and removal of polyps during colonoscopy has been demonstrated to decrease the risk of colon cancer development in individuals \[[@b1-ce-2019-062]\]. However, polypectomy during colonoscopy carries risks, including post-polypectomy bleeding (PPB), post-polypectomy syndrome, and perforation. PPB can be categorized into two groups: immediate PPB and delayed PPB. In immediate PPB, the endoscopist can almost always identify a bleeding complication at the time of polypectomy and perform endoscopic therapy at that time. Delayed PPB usually manifests hours to days after colonoscopy, with the patient presenting with signs or symptoms of hematochezia, acute blood loss anemia with possible hemodynamic instability, and end-organ damage (acute kidney injury, syncope, chest pain, dyspnea, etc.). A patient with significant hematochezia hours to days after colonoscopy should always raise a suspicion for delayed PPB. Although similar bleeding complications can occur after resection of polyps in the foregut, this review will focus on the current approaches in the management of PPB resulting from polypectomy in the colon.

RISK FACTORS
============

A number of patient-specific and polyp-specific risk factors have been identified in association with polypectomy ([Table 1](#t1-ce-2019-062){ref-type="table"}). A large study (including 15,285 colonoscopies) on PPB resulting from colonoscopies, performed as part of the English National Health Service Bowel Cancer Screening Programme, demonstrated the rate of PPB to be 0.4% per colonoscopy performed in patients at a high risk of colon polyps (positive fecal occult blood stool test) \[[@b2-ce-2019-062]\]. A systematic review and meta-analysis of studies on colorectal neoplastic lesions ≥20 mm that were managed with endoscopic polypectomy demonstrated that in 6,474 colonoscopies with large-polyp polypectomy, the rate of bleeding was 6.5%, which was significantly higher than that for small-polyp polypectomy \[[@b3-ce-2019-062]\].

A study by Kim et al. that included 5,152 patients undergoing colonoscopy (in which \>9,000 polyps were removed) showed multiple risk factors for immediate PPB \[[@b4-ce-2019-062]\]. Polyp-based multivariate analysis showed that age ≥65 years, comorbid cardiovascular or chronic renal disease, anticoagulant use, polyp size \>1 cm, laterally spreading polyp, thick polyp stalk, poor bowel preparation, and inadvertent cutting of a polyp before the intended application of current were all significant risk factors of PPB \[[@b4-ce-2019-062]\].

A large study by Zhang et al. that included 15,553 polypectomies showed multiple risk factors for delayed PPB \[[@b5-ce-2019-062]\]. Polyp size \>10 mm (odds ratio \[OR\], 4.6; 95% confidence interval \[CI\], 2.9--7.2), immediate PPB (OR, 2.9; 95% CI, 1.4--5.9), and colon polyp pathology (juvenile polyp: OR, 4.3; 95% CI, 1.8--11, Peutz-Jegher polyp: OR, 3.3; 95% CI, 1.0--10.7) were all associated with increased rates of PPB \[[@b5-ce-2019-062]\]. Another recent case-- control study demonstrated that polyp size and location in the colon were independent risk factors for delayed PPB \[[@b6-ce-2019-062]\]. The risk of bleeding increased by 13% for every 1 mm increase in polyp diameter. Polyps located in the right colon were more likely to bleed than those in the left colon or rectum (OR, 4.7; 95% CI, 1.9--11.6) \[[@b6-ce-2019-062]\]. A study of the English National Health Service Bowel Cancer Screening Programme supported these findings \[[@b7-ce-2019-062]\]. Of 130,831 colonoscopies with 167,208 polypectomies, the major risk factors for PPB were cecal location and increasing polyp size \[[@b7-ce-2019-062]\]. After adjustment for polyp size, the OR of PPB for a cecal polypectomy was found to be 13.5 (95% CI, 3.9--46.4) \[[@b7-ce-2019-062]\].

Uninterrupted antiplatelet agents (APAs) and anticoagulant medications have also been associated with higher rates of PPB. A recent systematic review and meta-analysis of 11 studies (with 9,307 patients) showed that use of aspirin and/ or nonsteroidal anti-inflammatory drugs (NSAIDs) was not a risk factor for immediate PPB (OR, 1.1; 95% CI, 0.6--2.1), but increased the risk of delayed PPB (OR, 1.7; 95% CI, 1.2--2.2) \[[@b8-ce-2019-062]\]. Furthermore, there is evidence of an increased risk of PPB while on clopidogrel treatment (OR, 9.7; 95% CI, 3.1--30.8) and with the combination of clopidogrel + aspirin (dual antiplatelet therapy) and/or NSAIDs (OR, 3.4; 95% CI, 1.3--8.8) \[[@b9-ce-2019-062]\]. Studies have demonstrated increased rates of PPB in both the immediate and delayed settings \[[@b10-ce-2019-062]\]. There have been reports of PPB rates as high as 22% in cases of colonoscopy with polypectomy performed with prophylactic clip closure in patients who are on heparin bridge anticoagulant therapy (compared with the rate of 1.9% in patients not on heparin bridge therapy in this study) \[[@b11-ce-2019-062]\]. Similar risks of delayed PPB with heparin bridge therapy have also been noted in other studies \[[@b12-ce-2019-062],[@b13-ce-2019-062]\]. A higher risk of PPB (51.7%) was noted in patients undergoing endoscopic mucosal resection (EMR) while on heparin bridge therapy \[[@b14-ce-2019-062]\]. Continued warfarin use has also previously been found to have an increased risk of PPB (OR, 13.4; 95% CI, 4.1--43.7) \[[@b15-ce-2019-062]\]. Increased costs of hospitalization have also been reported in association with heparin bridge therapy. A recent study \[[@b16-ce-2019-062]\] showed a 10-fold higher risk of PPB in patients on heparin bridge anticoagulation therapy than in those on interrupted warfarin therapy. Other risk factors for PPB were also identified and found to be similar to those reported in other studies ([Table 1](#t1-ce-2019-062){ref-type="table"}) \[[@b17-ce-2019-062]\].

With the advent of newer APAs and direct oral anticoagulants (DOACs) over the past few years, there has been an increasing need to study the effects of these agents on PPB and to identify risk factors that predispose patients to PPB. A study by Beppu et al. has shown that edoxaban (a direct factor Xa inhibitor) had the lowest PPB rate among the four current DOACs on the market and the use of DOACs (interrupted 1 day before the treatment procedure and restarted within 24 h after the procedure in this study) carried a similar safety profile, decreased the rate of delayed PPB, and reduced the length of hospital stay, compared with heparin bridge therapy \[[@b18-ce-2019-062]\]. A similar study by Yanagisawa et al. \[[@b19-ce-2019-062]\] showed comparable rates of delayed PPB between warfarin and all DOACs (no patients on edoxaban). Predictive models for PPB in patients receiving warfarin and DOACs, such as the Outcomes Registry for Better Informed Treatment score \[[@b20-ce-2019-062]\] and a risk-scoring model from China \[[@b21-ce-2019-062]\], have been proposed but are yet to be validated for widespread use. There are also studies reporting the risk of PPB with hot-snare (thermal) polypectomy (HSP) and coldsnare (nonthermal) polypectomy (CSP) in the background of APAs, warfarin, and DOACs, which are detailed in the next section. Overall, comprehensive prospective studies assessing the risk of PPB associated with newer APAs and DOACs are lacking and need to be addressed in the immediate future.

PREVENTION OF POST-POLYPECTOMY BLEEDING
=======================================

In patients taking APAs and anticoagulant medications, withholding these medications in the peri-colonoscopic period can pose significant risks of thrombo-embolic and cardiac events. Thus, the risk of withholding these medications must be carefully weighed against that of PPB. A review by Baron et al. \[[@b22-ce-2019-062]\] on the management of antithrombotic therapy in patients undergoing invasive procedures in all specialties was published in 2013, which classified nonthermal polypectomy (CSP) of small colonic polyps (\<10 mm) as a low-risk procedure and thermal polypectomy (HSP) of large polyps (≥10 mm) as well as EMR as high-risk procedures. The review made appropriate recommendations about the discontinuation and resumption of APAs and anticoagulants based on the bleeding risk of the procedure and risk of thrombo-embolic events on discontinuation of antithrombotic therapy. Thereafter, specific guidelines have been issued by the American Society for Gastrointestinal Endoscopy (ASGE) \[[@b23-ce-2019-062]\] and the British Society of Gastroenterology/European Society of Gastrointestinal Endoscopy (ESGE) \[[@b24-ce-2019-062]\], both in 2016, regarding the peri-procedural management of antithrombotic medications specifically for gastroenterological procedures. Both sets of guidelines have classified polypectomy (thermal and nonthermal) and EMR as high-risk procedures and have risk-stratified the indications for antithrombotic medications. Based on the risk assessment of indications for antithrombotic therapy, the risk of thrombo-embolic events on discontinuation, characteristics (pharmacokinetics and pharmacodynamics) of individual agents, and comorbidities of individual patients, recommendations have been provided for currently approved APAs and anticoagulants with respect to the timing of discontinuation before the procedure, need for heparin bridging, and timing of resumption after procedure completion. The guidelines also advise caution in high-risk indications for antithrombotic therapy and recommend liaising with the prescribing specialist (cardiologist, neurologist, etc.) regarding the timing of discontinuation. The two sets of guidelines are similar with respect to polypectomy, with the ASGE providing expanded recommendations on individual DOACs based on the patient's creatinine clearance. Experts recommend using these guidelines to create individual plans for patients based on their individual characteristics and comorbidities. The guidelines published by the Japan Gastroenterological Endoscopy Society in 2013 \[[@b25-ce-2019-062]\], with an update in 2017 specifically addressing DOACs \[[@b26-ce-2019-062]\], and those published by the Asian Pacific Association of Gastroenterology/Asian Pacific Society for Digestive Endoscopy \[[@b27-ce-2019-062]\] in 2018 have also provided similar recommendations.

There has been significant interest in the past few years in the individual bleeding risk associated with polypectomy of small (\<10 mm), large (10--19 mm), and very large (≥20 mm) polyps; in the individual bleeding risk associated with thermal polypectomy (HSP) and nonthermal polypectomy (CSP); and in modalities that can be deployed at the time of polypectomy to prevent immediate and/or delayed PPB.

There is evidence of a lower rate of delayed PPB with CSP than that with HSP. Individual studies \[[@b28-ce-2019-062],[@b29-ce-2019-062]\] and systematic reviews and meta-analyses \[[@b30-ce-2019-062]\] have shown that although HSP minimizes immediate PPB through thermal therapy, it carries a risk of damage to the deeper tissues and blood vessels, leading to delayed PPB. CSP, on the other hand, is associated with immediate PPB that can be treated at the time of polypectomy and with much lower delayed PPB rates. Meanwhile, the two techniques have comparable resection rates. A recent study \[[@b31-ce-2019-062]\] showed that the depth and size of the mucosal defect on the day after polypectomy was greater with HSP than with CSP, and this finding may also partially account for the higher rates of delayed PPB with HSP. The decision to use HSP is primarily determined by the polyp size and morphology (pedunculated vs. nonpedunculated). Most polyps encountered during colonoscopy are either diminutive (\<5 mm) or small (6--9 mm) nonpedunculated polyps. The current ESGE guidelines \[[@b32-ce-2019-062]\] recommend CSP as the preferred technique for the removal of subcentimeter (\<10 mm) polyps, with a recent meta-analysis \[[@b33-ce-2019-062]\] supporting this recommendation. A recent multicenter randomized controlled trial \[[@b34-ce-2019-062]\] showed that CSP is not inferior (comparable resection rate) to HSP for small nonpedunculated polyps with a superior safety profile (lower delayed PPB rate). These findings were also supported by a recent meta-analysis \[[@b35-ce-2019-062]\] that did not include the randomized controlled trial \[[@b34-ce-2019-062]\]. There has been a concerted effort to expand the use of CSP to large nonpedunculated polyps (≥10 mm). Recent systematic reviews and pooled-analyses \[[@b36-ce-2019-062],[@b37-ce-2019-062]\] showed excellent rates of resection comparable to those of HSP, with lower rates of delayed PPB than those of HSP. There were higher rates of immediate PPB with polyps ≥20 mm, which were effectively managed during the procedure.

Expanding the application of CSP to small pedunculated polyps (≤10 mm) has also been considered, with a recent study \[[@b38-ce-2019-062]\] showing low rates of immediate PPB in procedures involving endoscopic clipping and showing no delayed PPB. Further studies are required to assess the safety of CSP for pedunculated polyps. The general practice remains HSP for pedunculated polyps, given that penetrating blood vessels within the stalk is not uncommon.

As previously mentioned, the presence of antithrombotic medications (APAs, warfarin, DOACs) further adds complexity to determining the safety of CSP and HSP and the rates of associated immediate and delayed PPB. Several studies \[[@b39-ce-2019-062]-[@b41-ce-2019-062]\] and a prospective, multicenter, randomized controlled trial \[[@b42-ce-2019-062]\] have shown the safety of CSP for subcentimeter nonpedunculated polyps (\<10 mm) in the presence of continued use of APAs, warfarin, and DOACs with no increased risk of delayed PPB compared with HSP \[[@b43-ce-2019-062]\], even when multiple antithrombotic agents \[[@b44-ce-2019-062]\] were continued.

There is controversy about whether clipping mucosal defects ([Fig. 1](#f1-ce-2019-062){ref-type="fig"}) after polypectomy (HSP and CSP) may reduce the risk of subsequent delayed PPB. In a study of 524 large polyps (≥2 cm) in which 47.1% were not clipped and the others were clipped, there was a significantly decreased risk of delayed PPB in the group with prophylactic clipping of resection sites (1.8% clipped vs. 9.7% not clipped) \[[@b45-ce-2019-062]\]. Multivariate analysis showed that the absence of clipping (OR, 6.0; 95% CI, 2.0--18.5), a location proximal to the splenic flexure (OR, 2.9; 95% CI, 1.1--8.1), and polyp size were all associated with delayed PPB \[[@b45-ce-2019-062]\]. A subsequent multicenter randomized controlled study of prophylactic clipping vs. nonclipping polypectomy sites in polyps \<2 cm showed no significant difference between the two groups, suggesting a lack of benefit with clipping mucosal defects for polyps \<2 cm \[[@b46-ce-2019-062]\]. More recent studies have also reported similar findings, showing that prophylactic clipping of mucosal defects following polypectomy of nonpedunculated polyps \<20 mm and irrespective of location has not been effective in reducing the risk of delayed PPB, and is associated with higher costs with no definite benefits \[[@b47-ce-2019-062],[@b48-ce-2019-062]\]. In a recent multicenter, randomized trial of 1,900 patients undergoing polypectomy of large nonpedunculated colon polyps (≥20 mm), endoscopic clip closure of the mucosal defect was found to reduce the risk of PPB (3.3% vs. 9.6%) and the risk reduction appeared to be largely limited to polypectomies performed in the proximal colon \[[@b49-ce-2019-062]\]. In contrast, in a separate randomized trial in 1,098 patients undergoing polypectomy of nonpedunculated polyps ≥10 mm, there was no benefit with closure of mucosal defects using prophylactic endoscopic clipping in reducing the rate of delayed PPB, and this finding was consistent with that obtained for large polyps (≥20 mm) \[[@b50-ce-2019-062]\]. Several systematic reviews and meta-analyses \[[@b51-ce-2019-062]-[@b56-ce-2019-062]\] have consistently shown a similar lack of benefit of prophylactic endoscopic clipping of mucosal defects of nonpedunculated polyps up to 19 mm, with inconclusive benefits for nonpedunculated polyps ≥20 mm. This heterogeneity in polyps ≥20 mm could be due to variations in the polyp location that have not been accounted for in most studies, as was reported in the previously mentioned randomized trial \[[@b49-ce-2019-062]\] in which a benefit was noted only in the proximal colon. A recent study \[[@b57-ce-2019-062]\] proposed the use of a Doppler endoscopic probe to detect superficial (\<4 mm) arterial blood flow in the post-polypectomy mucosal defect to identify lesions that would benefit from prophylactic endotherapy (clipping, thermal therapy) and showed that mucosal defects ≥15 mm more likely contain arterial blood flow. Defects with arterial flow have a much higher risk of delayed PPB and may benefit from prophylactic endotherapy. This technology appears to be promising in detecting highrisk lesions and would need further prospective study before widespread implementation can be recommended. Another study proposed thermal therapy of visible vessels seen after EMR, with the results showing no benefit in the reduction of delayed PPB, supporting our previously mentioned hypothesis that delayed PPB primarily results from damage to vessels in deeper tissues during HSP. To avoid injury to deeper tissues in HSP, a recent study \[[@b58-ce-2019-062]\] compared the two most commonly used electrocautery settings and found no difference in the rates of resection or rates of delayed PPB.

Previous studies have suggested a potential benefit of performing prophylactic submucosal injection of an epinephrine solution before polypectomy \[[@b59-ce-2019-062],[@b60-ce-2019-062]\]. These studies, however, have been limited by their small size. A more definitive prospective, randomized multicenter trial of prophylactic injection of epinephrine solution before the resection of large colon polyps (\>10 mm) showed no significant difference in the immediate or delayed PPB rates in patients who received submucosal injection of epinephrine solution \[[@b61-ce-2019-062]\].

Given the increased risk of immediate PPB associated with large pedunculated polyps with thick stalks, some endoscopists routinely place a detachable snare (endoloop) around the stalk of a large pedunculated polyp before polypectomy. In a prospective, randomized study on the placement of a detachable snare on the stalk of a pedunculated polyp combined with injection of epinephrine solution compared with sole injection of epinephrine solution, there was a significantly decreased risk of immediate PPB in the combination group treated with detachable snare compared to the group given epinephrine injection alone \[[@b62-ce-2019-062]\]. A systematic review and meta-analysis recently demonstrated that both prophylactic mechanical therapy and injection therapy reduced immediate PPB, but had no effect on delayed PPB. The combination of both therapies, however, was not significantly better than either therapy alone \[[@b63-ce-2019-062]\].

MANAGEMENT OF POST-POLYPECTOMY BLEEDING
=======================================

The management of immediate PPB is relatively straightforward, if detected and addressed at the time of polypectomy. Every polypectomy resection site should be routinely examined after resection to check for the presence of muscle tissue (deep) injury, perforation, residual polyp, or bleeding. In the case of minimal oozing of blood from a polypectomy site ([Fig. 2](#f2-ce-2019-062){ref-type="fig"}), a small period of observation with water lavage often results in self-limited cessation of oozing. Further, in cases of slow oozing after polypectomy, the mucosal defect can be gently and directly suctioned with the scope tip for 30--60 s. This direct pressure on small bleeding capillaries often results in effective hemostasis.

When a more brisk or persistent immediate PPB is encountered, it is essential to have an effective field of view. For this, a water jet on the colonoscope is helpful, to allow for continued lavage of the bleeding site in order to identify the precise location of the bleeding source. Identifying a bleeding source is important for the targeted deployment of endoscopic therapy. The most commonly utilized option for significant immediate PPB is the use of through-the-scope (TTS) clips. In previous studies, the rate of endoscopic success with TTS clips has been high, with cessation of bleeding achieved in the vast majority of patients \[[@b64-ce-2019-062],[@b65-ce-2019-062]\]. In the series by Parra-Blanco et al. \[[@b65-ce-2019-062]\], there were no cases of recurrent bleeding.

The preferred method for deploying a clip in treating bleeding from the stalk of a pedunculated polyp is by deploying the clip perpendicular to the base of the stalk to ligate the feeder vessels \[[@b66-ce-2019-062]\]. For PPB occurring after sessile polyp removal, the goal is to directly tamponade the underlying blood vessel by maneuvering the clip and opposing the mucosa on both sides of the defect, when possible \[[@b67-ce-2019-062]\]. For very large endoscopic resection, the adjacent mucosal margins may not be approximated effectively at times. To ensure hemostasis, the area should be lavaged copiously while the TTS clip is closed but not deployed. If the area has no re-accumulation of red blood, then clip deployment is appropriate in that position \[[@b67-ce-2019-062]\].

Other methods of endoscopic hemostasis include direct thermal therapy, which is performed with bipolar cautery, snare tip, or thermal probes. In addition, for refractory oozing PPB, coagulation therapy with argon plasma coagulation can be applied to the resection bed. The electrosurgical settings vary depending on the preference of the provider and the system used; however, generally, caution should be exercised when performing thermal therapy in the right colon and cecum, given the thin colonic wall in the region \[[@b68-ce-2019-062]\]. There are no head-to-head prospective studies comparing thermal therapy to TTS clips for the management of PPB. The decision to use a certain method will depend on the clinical scenario, available equipment, and preference of the endoscopist. For instance, intraprocedural bleeding during large-polyp EMR can be effectively treated with snare-tip soft coagulation (STSC). This avoids the placement of TTS clips and/or larger thermal defects that can, at times, impair the effective completion of a large-polyp EMR. If STSC is not adequate, then intraprocedural bleeding during a large-polyp EMR can often be achieved using coagulating forceps. These techniques have been described in detail by Klein and Bourke \[[@b69-ce-2019-062]\].

For either immediate or delayed PPB, if standard hemostasis therapies including TTS clip application, epinephrine solution injection, thermal/coagulative therapy, and/or combinations thereof do not achieve hemostasis, there are newer hemostasis products available that can be utilized. The over-the-scope clip (OTSC; Ovesco Endoscopy, Tubingen, Germany) has been more extensively studied in the treatment of upper gastrointestinal bleeding but has also been demonstrated to be an effective salvage therapy option in patients with PPB \[[@b70-ce-2019-062]-[@b73-ce-2019-062]\]. Moreover, contact hemostasis powder spray (Hemospray; Cook Medical, Bloomington, IN, USA) has been used to successfully treat PPB \[[@b74-ce-2019-062]-[@b77-ce-2019-062]\]. Given that hemostasis powder will slough off some interval after treatment, studies \[[@b76-ce-2019-062],[@b77-ce-2019-062]\] have shown higher rates of re-bleeding within the first 72 h and that re-bleeding is more likely to occur with an actively spurting bleed and with a background of hemodynamic instability. It is, therefore, recommended to use Hemospray as a temporary bridge to a more definitive treatment and to repeat colonoscopy in 24--48 h after achieving initial hemostasis to perform definitive endoscopic therapy.

In cases of delayed PPB, the site of active bleeding can be endoscopically determined by repeating a colonoscopy or nonendoscopically via angiography or red blood cell nuclear scintigraphy \[[@b78-ce-2019-062]\]. Although most cases of delayed PPB can be effectively managed endoscopically, the decision to proceed with colonoscopy and the timing of colonoscopy should be individualized. First, the patient should be assessed for hemodynamic instability (including orthostasis) and the duration, frequency, and volume of hematochezia, in addition to laboratory evaluation with complete blood count and prothrombin time/international normalized ratio. Resuscitation of blood volume and infusion of crystalloid to achieve hemodynamic stability should be prioritized.

Sonnenberg \[[@b79-ce-2019-062]\] conducted a decision analysis study and showed that proceeding with colonoscopy for delayed PPB was beneficial in identifying and treating a bleeding lesion in 22% of the cases, with a number needed to treat of 4.5 patients. The author concluded that it would be beneficial to attempt a repeat colonoscopy, but, at the same time, it is reasonable to manage some patients expectantly. In a study by Derbyshire et al., the requirement for blood transfusion and a drop in hemoglobin of \>2 g/dL were predictors of the need for a therapeutic intervention \[[@b2-ce-2019-062]\]. Ma and Bourke proposed an algorithm for the management of bleeding after large-polyp EMR \[[@b67-ce-2019-062]\]. In this algorithm, the authors recommended bowel preparation and colonoscopy for patients with ongoing bleeding, and found that the factors associated with poor outcome were American Society of Anesthesiologists grade ≥2, hemodynamic instability, hourly or more frequent hematochezia, low admission hemoglobin (\<12.0 g/dL), or the requirement for blood transfusion \[[@b67-ce-2019-062]\]. Generally, an expedited bowel preparation followed by expeditious diagnostic and therapeutic colonoscopy once a patient is stabilized is appropriate. When the culprit polypectomy site is found, we recommend clearing the area of any residual blood and blood clot in order to identify the precise source of bleeding within the polypectomy defect. The area can be subsequently treated with clips or forceps coagulation or some combination with epinephrine injection \[[@b67-ce-2019-062],[@b68-ce-2019-062],[@b80-ce-2019-062]\]. In general, extensive thermal therapy is discouraged in a post-polypectomy resection site to avoid the risk of delayed perforation, as the mucosal resection site is often ulcerated. As mentioned previously, the use of OTSCs or hemostatic powder can be considered for refractory bleeding lesions. For patients that remain hemodynamically unstable despite resuscitative efforts, consultations for urgent interventional radiology evaluation and/or urgent surgical evaluation are prudent.

CONCLUSIONS
===========

PPB is one of the most common complications of endoscopic polypectomy. There are multiple risk factors related to patient and polyp characteristics that should be considered. In most cases, immediate PPB can be effectively managed endoscopically when recognized and managed promptly. Delayed PPB can manifest in a myriad of ways. In severe delayed PPB, resuscitation for hemodynamic stabilization should be prioritized, followed by endoscopic evaluation and therapy once the patient is stabilized. CSP for sessile polyps \<20 mm seems to be safe and has a lower incidence of delayed PPB. Future areas of research in PPB include the risks of DOACs, risks of specific electrosurgical settings (HSP vs. CSP), and prospective comparative evaluation of newer hemostasis agents (hemostatic spray powder, OTSC, etc.).
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###### 

Risk Factors Associated with Polypectomy

  -------------------------------------------------------------------------------
  Polyp size (\>10 mm)
  Pedunculated polyp with a thick stalk
  Polyp pathology (juvenile polyp, Peutz-Jegher polyp)
  Polyp location in the right colon (a cecal location carries the highest risk)
  Patient age ≥65 yr
  Comorbid cardiovascular or chronic renal disease
  Warfarin, DOACs
  Aspirin/NSAIDs
  P2Y12 receptor antagonists (e.g., clopidogrel)
  GPIIb/IIIa inhibitors (e.g., abciximab)
  PAR-1 inhibitors (e.g., vorapaxar)
  Heparin bridge anticoagulation therapy
  -------------------------------------------------------------------------------

DOACs, direct oral anticoagulants; NSAID, nonsteroidal anti-inflammatory drug; PAR-1, protease-activated receptor-1.
